Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Video courtesy of NIHR

On International Clinical Trials Day, the RECOVERY Trial team are reflecting on an unprecedented collaboration that has seen over 10,000 patients enrolled in the world’s largest trial of potential COVID-19 treatments.

20 May is the anniversary of recruitment into what is thought to be the first clinical trial in 1747. At a time when scurvy was rife among seamen, James Lind, then a surgeon’s mate on the HMS Salisbury, followed a hunch that it was caused by putrefaction of the body. Lind noted that ‘No physician conversant with this disease at sea had undertaken to throw light upon the subject’. He recruited 12 sailors and allocated two men to each of six different treatments (vinegar, nutmeg, oranges and lemons, sea water, cider, and elixir of vitriol) and found that those given oranges and lemons experienced ‘the most sudden and good visible effects.’

273 years later, clinical research at Oxford University is at the forefront of global efforts to tackle the coronavirus pandemic. The RECOVERY Trial is the world’s biggest trial of potential COVID-19 treatments and the fastest ever recruiting individually randomised controlled trial. It was set up in record time, taking just nine days from conception to launch, and has recruited over 10,000 patients in 176 UK hospitals in just two months.

Read the full story on the RECOVERY Trial website

Read more about how the RECOVERY Trial was set-up

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.